Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Acute Myeloid Leukemia | Research

Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis

Authors: Yang Qiu, Lu Bai, Haosen Zhao, Xifan Mei

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Acute myeloid leukaemia (AML) is a fatal haematopoietic malignancy and is treated with the conventional combination of cytarabine (Ara-C) and daunorubicin (Dau). The survival rate of AML patients is lower due to the cardiotoxicity of daunorubicin. Clinically, homoharringtonine (HHT) plus Ara-C has been reported to be equally effective as Dau plus Ara-C in some types of AML patients with less toxic effects. We utilized the clinical use of homoharringtonine in combination with Ara-C to test its combination mechanism. We found that the insensitivity of AML cells to cytarabine-induced apoptosis is associated with increased Mcl-1 stability and p38 inactivation. HHT downregulates Mcl-1, phosphorylates H2AX and induces apoptosis by activating p38 MAPK. Inactivation of p38 through inhibitors and siRNA blocks apoptosis, H2AX phosphorylation and Mcl-1 reduction. HHT enhances Ara-C activation of the p38 MAPK signalling pathway, overcoming Ara-C tolerance to cell apoptosis by regulating the p38/H2AX/Mcl-1 axis. The optimal ratio of HHT to Ara-C for synergistic lethality in AML cells is 1:4 (M/M). HHT synergistically induces apoptosis in combination with Ara-C in vitro and prolongs the survival of xenografts. We provide a new mechanism for AML treatment by regulating the p38 MAPK/H2AX/Mcl-1 axis to improve cytarabine therapy.
Appendix
Available only for authorised users
Literature
1.
Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. New England journal of medicine. N Engl J Med. 2015;373:1136–52.PubMedCrossRef
2.
Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.PubMedCrossRef
3.
Martin MG, Abboud CN. Induction therapy for elderly patients with acute myeloid leukemia. Blood Rev. 2008;22:311–20.PubMedCrossRef
4.
5.
Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–26.PubMedCrossRef
6.
Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012;26:2061–8.PubMedPubMedCentralCrossRef
7.
DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL 2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93:401–7.PubMedCrossRef
8.
Deng G, Shen J, Yin M, et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J Biol Chem. 2015;290:762–74.PubMedCrossRef
9.
Jin J, Wang JX, Chen FF, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013;14:599–608.PubMedCrossRef
10.
Yu W, Mao L, Qian J, et al. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience. Ann Hematol. 2013;92:1091–100.PubMedCrossRef
11.
Wang J, Lü S, Yang J, et al. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China. J Hematol Oncol. 2009;2:32.PubMedPubMedCentralCrossRef
12.
Glaser SP, Lee EF, Trounson E, et al. Anti-apoptotic mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26(2):120–5.PubMedPubMedCentralCrossRef
13.
14.
Zhang J, Wang Y, Yin C, et al. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/mcl-1/p-Chk1 axis. Cell Death Dis. 2022;13(4):379.PubMedPubMedCentralCrossRef
15.
Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia. 1992;6:1189–91.PubMed
16.
Wu L, Li X, Su J, et al. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Leuk Lymphoma. 2009;50:1461–7.PubMedCrossRef
17.
Qiu Y, Li Y, Chai M, et al. The GSK3β/mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors. Cell Death Discov. 2023;9(1):44.PubMedPubMedCentralCrossRef
18.
Tang R, Faussat AM, Majdak P, et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther. 2006;5:723–31.PubMedCrossRef
19.
Lindqvist L, Vikström I, Chambers J, et al. Translation inhibitors induce cell death by multiple mechanisms and mcl-1 reduction is only a minor contributor. Cell Death Dis. 2012;3:e409.PubMedPubMedCentralCrossRef
20.
Towatari M, Iida H, Tanimoto M, et al. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia. 1997;11:479–84.PubMedCrossRef
21.
22.
Hsiao PW, Chang CC, Liu HF, et al. Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Toxicol Appl Pharm. 2007;222:97–104.CrossRef
23.
Dong Y, Xiong M, Duan L, et al. H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib. Apoptosis. 2014;19:1281–92.PubMedCrossRef
24.
Sluss HK, Davis RJ. H2AX is a target of the JNK signaling pathway that is required for apoptotic DNA fragmentation. Mol Cell. 2006;23(2):152–3.PubMedCrossRef
25.
Huelsemann MF, Patz M, Beckmann L, et al. Hypoxia-induced p38 MAPK activation reduces mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. Leukemia. 2015;29(4):981–4.PubMedCrossRef
26.
Leite M, Quinta-Costa M, Leite PS, et al. Critical evaluation of techniques to detect and measure cell death--study in a model of UV radiation of the leukaemic cell line HL60. Anal Cell Pathol. 1999;19(3–4):139–51.PubMedPubMedCentralCrossRef
27.
Azijli K, Yuvaraj S, van Roosmalen I, et al. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by mcl-1. Apoptosis. 2013;18(7):851–60.PubMedCrossRef
28.
Allan EK, Holyoake TL, Craig AR, Jørgensen HG. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia. 2011;25(6):985–94.PubMedCrossRef
29.
30.
Yin S, Wang R, Zhou F, et al. Bcl-xL is a dominant antiapoptotic protein that inhibits homoharringtonine-induced apoptosis in leukemia cells. Mol Pharm. 2011;79:1072–83.CrossRef
31.
32.
Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv. 2007;7:216.PubMedCrossRef
33.
Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–6.PubMedCrossRef
34.
Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharm Rev. 2006;58:621–81.PubMedCrossRef
35.
Nishioka C, Ikezoe T, Yang J, et al. Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. Apoptosis. 2009;14:1108–20.PubMedCrossRef
36.
Edwards SW, Derouet M, Howse M, et al. Regulation of neutrophil apoptosis by mcl-1. Biochem Soc Trans. 2004;32:489–92.PubMedCrossRef
37.
Guo L, Eldridge S, Furniss M, et al. Role of mcl-1 in regulation of cell death in human induced pluripotent stem cell-derived cardiomyocytes in vitro. Toxicol Appl Pharmacol. 2018;1(360):88–98.CrossRef
38.
39.
Huang HL, Hsieh MJ, Chien MH, et al. Glabridin mediate caspases activation and induces apoptosis through JNK1/2 and p38 MAPK pathway in human promyelocytic leukemia cells. PLoS One. 2014;9:e98943.PubMedPubMedCentralCrossRef
40.
Abraham M, Klein S, Bulvik B, et al. The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. Leukemia. 2017;31:2336–46.PubMedCrossRef
41.
Chen R, Guo L, Chen Y, et al. Homoharringtonine reduced mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 2011;117:156–64.PubMedPubMedCentralCrossRef
42.
Saffar AS, Dragon S, Ezzati P, et al. Phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase regulate induction of mcl-1 and survival in glucocorticoid-treated human neutrophils. J Allergy Clin Immun. 2008;121:492-8.e10.PubMedCrossRef
43.
Kumar TS, Kari V, Choudhary B, et al. Anti-apoptotic protein BCL2 downregulates DNA end joining in cancer cells. J Biol Chem. 2010;285:32657e32670.CrossRef
44.
Zhan Q, Bieszczad CK, Bae I, et al. Induction of BCL2 family member MCL1 as an early response to DNA damage. Oncogene. 1997;14:1031e1039.CrossRef
45.
Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol. 2012;920:613–26.PubMedCrossRef
46.
Wergeland L, Sjøholt G, Haaland I, et al. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Mol Cancer. 2007;6:33.PubMedPubMedCentralCrossRef
47.
Kim BM, Lee KH, Hong IS, et al. p38 mitogen-activated protein kinase is a key regulator of 5-phenylselenyl-and 5-methylselenyl-methyl-2′-deoxyuridine-induced apoptosis in human HL-60 cells. Biochem Bioph Res Co. 2012;417:237–44.CrossRef
48.
Wu XP, Xiong M, Xu CS, et al. Resveratrol induces apoptosis of human chronic myelogenous leukemia cells in vitro through p38 and JNK-regulated H2AX phosphorylation. Acta Pharmacol Sin. 2015;36:353–61.PubMedPubMedCentralCrossRef
49.
Xie C, Edwards H, Caldwell JT, et al. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Mol Oncol. 2015;9(2):409–21.PubMedCrossRef
50.
Thornton TM, Rincon M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci. 2009;5(1):44–51.PubMedCrossRef
51.
Jamil S, Stoica C, Hackett TL, et al. MCL-1 localizes to sites of DNA damage and regulates DNA damage response. Cell Cycle. 2010;9:2915–27.CrossRef
52.
53.
Dicko A, Mayer LD, Tardi PG. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin Drug Del. 2010;7:1329–41.CrossRef
54.
Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5: 1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123:3239–46.PubMedPubMedCentralCrossRef
55.
Cortes JE, Lin TL, Asubonteng K, et al. Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial. J Hematol Oncol. 2022;15:155.PubMedPubMedCentralCrossRef
Metadata
Title
Homoharringtonine enhances cytarabine-induced apoptosis in acute myeloid leukaemia by regulating the p38 MAPK/H2AX/Mcl-1 axis
Authors
Yang Qiu
Lu Bai
Haosen Zhao
Xifan Mei
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12286-7

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Prognostic value of pre-treatment [18F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis

Systematic Review

The role of piRNAs in predicting and prognosing in cancer: a focus on piRNA-823 (a systematic review and meta-analysis)

Research

HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study

Research

Preimmunization with Listeria-vectored cervical cancer vaccine candidate strains can establish specific T-cell immune memory and prevent tumorigenesis

Study Protocol

Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients – a randomized controlled trial. (OxaNeuro)

Research

Facilitators and barriers of HPV vaccination: a qualitative study in rural Georgia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits